Tag: Europe
-
Trial Shows Nasal Filter Helps Relieve Hay Fever Symptoms
7 March 2014. A clinical trial at Aarhus University in Denmark shows a small filter placed in the nose reduced symptoms of hay fever among allergy sufferers, compared to a placebo. The inventor of the filter, Peter Kenney, a doctoral candidate at Aarhus, and colleagues presented their findings earlier this week at a meeting of…
-
Gene Modified Potatoes Developed with Blight Resistance
24 February 2014. Researchers at The Sainsbury Laboratory in Norwich, U.K. developed and field tested a new type of potato with greater genetically modified resistance to late blight, a long-time scourge of potato growers. The team led by Sainsbury plant biologist Jonathan Jones reported its findings online last week in the journal Philosophical Transactions of…
-
Belgium-U.S. Consortium Developing Lung Image Technology
11 February 2014. A group of companies and universities in Belgium and the U.S. are collaborating on an advanced imaging technology to spot signs of lung transplant rejection earlier in a patient’s recovery. Fluidda nv in Kontich, Belgium is leading the collaboration, with additive manufacturing company Materialise in Leuven, Belgium, and universities in Belgium (University…
-
Engineered Hemp Delivers High Volume of Healthy Oleic Acid
10 February 2014. Biologists at University of York in the U.K. developed a new form of hemp plant that produces seeds with oil containing a high volume of oleic acid, a nutritious fatty acid like that found in olive oil. The team led by York’s Ian Graham, who heads the university’s biology department, published its…
-
Shire to End Major Depression Drug Booster Development
7 February 2014. Shire PLC, a pharmaceutical company in the U.K., will end trials of its drug Vyvanse as a supplement to anti-depressants for treating major depressive disorder. The company made the decision following results of two late-stage clinical trials that show the drug failed to meet the studies’ effectiveness objectives. Vyvanse (lisdexamfetamine dimesylate) is…
-
Sense of Touch Restored to Amputee’s Prosthetic Hand
5 February 2014. Biomedical engineers and computer scientists at Ecole Polytechnique Federale de Lausanne (EPFL) in Switzerland developed a sensory feedback system for an amputee’s prosthetic hand to control grasping and sense stiffness and shapes of objects. The findings of the Lifehand 2 team led by EPFL’s Silvestro Micera, with colleagues from other institutions in Europe,…
-
Biopharma, University Partner on Blood Cancer Immunotherapy
29 January 2014. Kiadis Pharma B.V., a biopharmaceutical company in Amsterdam, is collaborating with a research group at Technical University of Munich to identify immune-system cells for treating leukemia in the company’s immunotherapy product for blood cancers. Financial aspects of the partnership were not disclosed, although the company says the Munich research is funded, at…
-
Techniques Boost Range, Accuracy of Wireless ID Signals
Engineers at University of Cambridge in the U.K. developed techniques to vastly improve the range and accuracy of passive radio-frequency identification (RFID) tags used to identify passports, luggage, and goods in transit. The team led by Cambridge research fellow Sabesan Sithamparanathan published its findings online in the journal IEEE Transactions on Antennas and Propagation (paid…
-
FDA Fast-Track Granted to Cancer Therapy Side-Effects Drug
BioAlliance Pharma SA in Paris says its drug candidate to treat inflammation of the mucus membranes in the mouth, resulting from chemo- or radiation therapy to treat cancer, received fast-track status from the U.S. Food and Drug Administration. Validive, the drug’s brand name, is designed for patients with head and neck cancers. Oral mucositis is…
-
Cancer Organizations, Biotech Partner on Drug Discovery
Institute of Cancer Research and Cancer Research Technology in London, and the drug discovery company Nuevolution A/S in Copenhagen, are collaborating on identifying leads for new cancer treatments that act on a promising biological pathway. The agreement includes the option to co-develop therapies from candidates identified in the project, but financial aspects of the deal…